secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001213900-24-066613
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics Provides Q2 2024 Corporate Update and Financial Results
-----------------------------------------------------------------------------

- Collaborated with Abbott to advance tecarfarin for LVAD patients using HeartMate 3 device.
- Received FDA Orphan Drug Designation in April 2024 for preventing blood clots and strokes in LVAD patients.
- Q2 2024 operating expenses (ex-non-cash) totaled $2.3 million; cash used in operations was $1.5 million.
- Cash balance as of June 30, 2024 was $5.0 million.
- CEO Quang Pham highlighted progress on pivotal trial and LVAD study protocol development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024066613/0001213900-24-066613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024066613/ea021083501-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-066613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer